InDevR is a technology company.
InDevR has raised $16.0M across 2 funding rounds.
InDevR has raised $16.0M in total across 2 funding rounds.
InDevR has raised $16.0M in total across 2 funding rounds.
InDevR's investors include Adjuvant Capital.
InDevR is a Boulder, Colorado-based biotechnology company specializing in analytical technologies that accelerate vaccine development and manufacturing.[1][2] It develops the VaxArray platform, a multiplexed immunoassay system for potency testing, antigen characterization, and quality control of vaccines including mRNA, protein-based, polysaccharide, conjugate, and viral vector types, alongside the CypherOne system for automated hemagglutination assays.[2][3] These tools serve pharmaceutical companies, research institutions, and biotherapeutics manufacturers by solving challenges in rapid, standardized testing from R&D to release, enabling faster optimization, scale-up, and regulatory compliance.[1][3][4] InDevR demonstrates growth through product expansions like mRNA analytics and the 2024 launch of Expert Services for custom assay development.[1][4]
Founded in 2003 in Boulder, Colorado, InDevR emerged to address gaps in vaccine analytics, initially focusing on automated multiplex immunoassay solutions.[1][2] The company has evolved from protein-based vaccine tools—launching the VaxArray platform in 2014 with its benchtop imaging system, software, and reagent kits—to broader biotherapeutics, including mRNA and nucleic acid assays in response to pandemic-driven needs.[1][2] Key milestones include filing 12 patents on topics like vaccines, viral diseases, and imaging systems (e.g., a 2021 granted patent for parallel imaging), and building a reputation through collaborations with global pharma leaders.[1][3] This trajectory reflects adaptation to market demands for high-throughput, user-friendly tools in bioprocessing.[1][4]
InDevR rides the post-pandemic vaccine acceleration trend, where mRNA and novel biotherapeutics demand faster, scalable analytics amid global pressures for rapid deployment and supply chain resilience.[1][3][4] Timing aligns with surging needs for standardized potency testing to meet regulatory hurdles (e.g., FDA/EMA), as traditional single-plex assays bottleneck scale-up.[2][3] Market forces like rising biopharma R&D spend on vaccines—fueled by ongoing threats like influenza, COVID variants, and emerging pathogens—favor InDevR's multiplexed, automated tools that cut time-to-result and costs.[1][5] It influences the ecosystem by partnering with pharma giants, driving adoption of microarray-based methods, and enabling cell therapy applications, thus lowering barriers to accessible therapies.[3][4]
InDevR is primed to expand via Expert Services and VaxArray enhancements, targeting surging demand for next-gen vaccine analytics in a market projected to grow with annual flu shots, boosters, and pandemic preparedness.[4] Trends like AI-driven bioprocessing and personalized vaccines will amplify its multiplex edge, potentially through more nucleic acid kits and automation integrations. Its influence may evolve from niche innovator to essential infrastructure for global biomanufacturing, solidifying leadership as biotech races to deliver faster, safer vaccines—echoing its origins in solving analytical hurdles for tomorrow's therapeutics.[1][2][4]
InDevR has raised $16.0M across 2 funding rounds. Most recently, it raised $9.0M Series B in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $9.0M Series B | Adjuvant Capital | |
| Sep 1, 2019 | $7.0M Series A | Adjuvant Capital |